FDA ReviewedUpdated July 5, 2026

Mounjaro Guide

Mounjaro is the brand-name formulation of tirzepatide FDA-approved for type 2 diabetes, manufactured by Eli Lilly. It is prescribed weekly by injection and has become extremely popular off-label for weight loss given its superior efficacy data. Like Ozempic, Mounjaro is often prescribed for weight management while awaiting broader obesity indications.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

At a Glance

Generic NameTirzepatide
Brand NamesMounjaro
FDA StatusFDA-approved for type 2 diabetes (May 2022). Off-label use for weight loss is common; the weight management indication is covered by Zepbound (FDA-approved November 2023).[1]
Approval DateMay 13, 2022[1]

How Mounjaro Works

Mounjaro's tirzepatide activates both GIP and GLP-1 receptors — making it a "dual agonist" or "twincretin." For diabetes, this dual action powerfully lowers blood sugar by increasing insulin secretion and reducing glucagon. The same pathways simultaneously reduce appetite, slow gastric emptying, and appear to act directly on fat cells — producing the highest weight loss rates of any approved medication.[2][3]

Dosing Schedule

Mounjaro uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–42.5mg/week
Weeks 5–85mg/week
Weeks 9–127.5mg/week
Weeks 13–1610mg/week
Weeks 17–2012.5mg/week
Week 21+15mg/week (max)

Side Effects

Common: nausea (12–18%), diarrhea (13–16%), vomiting (5–9%), constipation (5–7%), decreased appetite, abdominal pain, injection site reactions. Side effects typically improve after the first 4–8 weeks. Serious (rare): pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SURPASS-2 trial, Mounjaro (tirzepatide 15mg) reduced HbA1c by 2.46 percentage points and produced 12.4 lbs more weight loss than semaglutide 1mg. Sub-analyses showed 41% of participants achieved an HbA1c below 5.7% — essentially normal blood sugar levels.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Mounjaro

These telehealth providers offer access to tirzepatide or compounded equivalents with online consultations and home delivery.

7.5/ 10

Effecty

Best for: nationwide compounded semaglutide with brand-name fallback

★★★★☆3.8

Editorial score · methodology

$60/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Effecty review →
7.3/ 10

altRX

Best for: the only platform offering all four brand-name GLP-1s plus compounded

★★★★☆3.7

Editorial score · methodology

$149/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full altRX review →
7.1/ 10

Levity

Best for: Patients wanting all-inclusive branded GLP-1 pens and willing to pay premium cash prices

★★★★☆3.6

Editorial score · methodology

$1199/mo
BrandTirzepatideSemaglutide
Get StartedRead full Levity review →
7.0/ 10

Eve

Best for: women's-health GLP-1 with compounded or brand-name access

★★★★☆3.5

Editorial score · methodology

$195/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Eve review →
7.0/ 10

Vital Edge

Best for: people who want transparent flat-fee GLP-1 pricing with oral and brand-name options

★★★★☆3.5

Editorial score · methodology

$199/mo
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Vital Edge review →
6.8/ 10

NowPatient

Best for: Brand-name GLP-1 access without a compounded route

★★★☆☆3.4

Editorial score · methodology

$1069/mo
BrandTirzepatideSemaglutideLiraglutide
Get StartedRead full NowPatient review →

Cost Comparison

Mounjaro cost & pricing →Savings & coupons →Side effects →Dosing & titration →How to get it →

Starting prices for compounded GLP-1 medications from top providers, sorted cheapest first. Compounded tirzepatide from licensed 503A and 503B pharmacies is legal under federal compounding law[4], with additional tolerances historically allowed while the molecule has appeared on the FDA Drug Shortage List[5]. Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose and promo availability.

ProviderStarting Price
Vital Edge$835/moVisit
NowPatient$1069/moVisit
altRX$1249/moVisit
Levity$1299/moVisit
Effecty$1300/moVisit
Eve$1399/moVisit
Ark Health$1499/moVisit

Mounjaro Head-to-Head Comparisons

Short-form verdict pages comparing Mounjaro to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

Mounjaro vs Ozempic
SURPASS-2 head-to-head: Mounjaro 15mg dropped weight 11.2 kg vs Ozempic 1mg's 5.7 kg at 40 weeks. Ozempic wins on proven CV outcomes (SUSTAIN-6 MACE -26%).
Last verified 2026-05-27
Mounjaro vs Zepbound
Mounjaro and Zepbound are the same molecule (tirzepatide) from Eli Lilly — Mounjaro is FDA-labeled for type 2 diabetes; Zepbound for obesity and obstructive sleep apnea.
Last verified 2026-05-27
Mounjaro vs Wegovy
Mounjaro is FDA-labeled for type 2 diabetes only; Wegovy is FDA-labeled for obesity + CV risk reduction. SURMOUNT-5 head-to-head: tirzepatide -20.2% vs semaglutide -13.7%.
Last verified 2026-05-27
Mounjaro vs Trulicity
Both made by Eli Lilly. Mounjaro 15 mg cut A1C ~2.3% and weight ~12.4% in SURPASS trials vs Trulicity 1.5 mg ~1.1% A1C and ~3 kg. Trulicity keeps the CV outcome label (REWIND) and a pediatric indication.
Last verified 2026-05-28
Mounjaro vs Foundayo
Foundayo (orforglipron) is Lilly's new daily oral non-peptide GLP-1 — FDA-approved for obesity April 2026, -11.1% TBWL in ATTAIN-1. Mounjaro is the weekly tirzepatide injection labeled for T2D only.
Last verified 2026-05-28
Mounjaro vs Saxenda
Mounjaro is weekly tirzepatide for type 2 diabetes; Saxenda is daily liraglutide for obesity. Different drugs, different labels, different schedules — patients rarely choose between them.
Last verified 2026-05-28

See all drug-vs-drug verdicts.

Mounjaro Patient Questions, Answered

Real patient questions about Mounjaro pulled from named subreddits and answered with peer-reviewed trial data.

Top 10 Tirzepatide Questions from Reddit, Answered with Trial Data
10 questions · 11 PubMed citations
Last verified 2026-05-27
Top 10 GLP-1 Insurance Coverage Questions from Reddit, Answered
10 questions · 12 PubMed citations
Last verified 2026-05-28
Top 10 GLP-1 Injection Technique Questions from Reddit, Answered with FDA Labels
10 questions · 11 PubMed citations
Last verified 2026-05-28

Mounjaro Reference Cards

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Mounjaro Dose Increase Timing (2026 Cheat Sheet)
FDA-label Mounjaro titration on one page — the 6-dose ladder, the A1C threshold that says “step up”, the GI threshold that says “hold”, missed-dose protocol, and the red-flag side effects that mean call the prescriber. T2D-labeled use only; weight loss is off-label here. DailyMed-sourced, current 2026.
5 min read · Last verified 2026-05-27
GLP-1 Injection Site Rotation: 8-Week Cheat Sheet (2026)
Wegovy, Ozempic, Zepbound, and Mounjaro all share the same three FDA-approved injection sites: abdomen, front of thigh, and back of upper arm. Reusing the same spot week after week causes lipohypertrophy — thickened fatty tissue that absorbs the drug erratically, leaving appetite suppression and weight-loss results inconsistent. This cheat sheet maps the approved sites, gives an 8-week rotation example, and lists the technique mistakes that send users back to the prescriber.
4 min read · Last verified 2026-05-28
GLP-1 to GLP-1 Switching (2026 Cheat Sheet)
Wegovy → Zepbound, Ozempic → Mounjaro, Saxenda → Wegovy — FDA labels do not address head-to-head switching directly. Starting-dose matrix, wait times between drugs, and red flags during the transition on one scannable page.
5 min read · Last verified 2026-05-28

Ranked PubMed Studies on Mounjaro

Curated lists of the highest-impact peer-reviewed studies on Mounjaro and related GLP-1 drugs. Every PMID live-verified via PubMed esummary.

Top 10 PubMed Studies on Tirzepatide for Weight Loss (2026)
Ten peer-reviewed tirzepatide weight-loss studies anchored to the SURMOUNT program (SURMOUNT-1 through SURMOUNT-5, plus SURMOUNT-CN and SURMOUNT-OSA), the SYNERGY-NASH liver-fibrosis trial, the SUMMIT HFpEF trial, and the SURPASS-2 head-to-head against semaglutide. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified 2026-05-27

Related Research on Mounjaro

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Endoscopic Sleeve Gastroplasty (ESG): The Evidence vs GLP-1s and Surgery
Endoscopic sleeve gastroplasty (ESG) is an incisionless stomach-tightening procedure that produced 13.6% weight loss in the MERIT randomized trial - on par with semaglutide, below tirzepatide and surgery. The honest evidence on efficacy, safety, cost, reversibility, and how it compares to a GLP-1.
12 min read12 citations
Gastric Balloon vs GLP-1: Which Wins on Weight Loss, Durability, and Safety?
No head-to-head trial exists, but the shape is clear: a temporary 6-month gastric balloon delivers ~7-15% weight loss that partly reverses after removal, versus a GLP-1's ongoing ~15-21% sustained while taken. The balloon also carries FDA death reports a GLP-1 does not. For most people a GLP-1 or ESG is stronger; the balloon's niche is a short-term jump-start.
10 min read7 citations
ESG vs GLP-1 (Semaglutide and Tirzepatide): The Head-to-Head Evidence
A one-time incisionless procedure or a weekly injection for life? ESG produced ~13.6-16% weight loss vs ~14.9% for semaglutide and ~20.9% for tirzepatide, but no head-to-head trial exists. Efficacy, durability, cost over time, risk, and the combination that beats either alone.
12 min read6 citations
Zepbound (Tirzepatide) and Sex Drive in Women: The Evidence
Zepbound is the largest-weight-loss GLP-1/GIP brand, so its weight-loss-mediated boost to female sexual function may be the biggest of any drug — yet no trial has ever measured female libido as an endpoint. What the evidence supports, plus PCOS and the contraception warning.
10 min read14 citations
Zepbound and Erectile Dysfunction: The Biggest Weight-Loss Lever for ED?
Zepbound (tirzepatide) produces the largest weight loss of any approved agent (SURMOUNT-1 -20.9%), so it offers the biggest weight-mediated erectile opportunity. But there is no direct ED-endpoint trial and no head-to-head vs semaglutide - plausible, not proven.
10 min read11 citations
Mounjaro and Erectile Dysfunction in Type 2 Diabetes: The Dual-Driver Case
Diabetic ED is extremely common. Mounjaro (tirzepatide) improves both glycemia and weight - the two biggest reversible drivers of ED in diabetic men. No tirzepatide trial measured erections, and established neuropathy caps recovery, but the mechanism is well-aimed.
10 min read11 citations

Frequently Asked Questions

Sources & methodology — as of July 2026
  1. 1.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SURPASS-2 Trial — Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (Frías JP et al.)— New England Journal of Medicine.PMID: 34170647.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.